Form 8-K Viridian Therapeutics, For: Sep 10

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Form 8-K Viridian Therapeutics, For: Sep 10

Viridian Therapeutic (VRDN) PT Raised to $31 at Goldman Sachs

September 12, 2024 5:07 AM EDT

Goldman Sachs analyst Richard Law raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $31.00 (from $25.00) while maintaining a Buy rating.

The analyst comments "We update our model to reflect increased POS for veligrotug (VRDN-001) following positive topline results from the Ph. 3 THRIVE... More

Viridian Therapeutic (VRDN) PT Raised to $40 at Stifel

September 10, 2024 1:08 PM EDT

Stifel analyst Alex Thompson raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $40.00 (from $33.00) while maintaining a Buy rating.

The analyst comments "We are increasing our PoS for VRDN-001/003 to 80% from 66% following positive topline data from the Ph3 THRIVE study (Our Take... More

Viridian Therapeutic (VRDN) PT Raised to $56 at BTIG

September 10, 2024 11:41 AM EDT

BTIG analyst Julian Harrison raised the price target on Viridian Therapeutic (NASDAQ: VRDN) to $56.00 (from $46.00) while maintaining a Buy rating.

The analyst comments "15wk THRIVE (active TED Phase 3) data show veligrotug (fka VRDN-001) with at least comparable proptosis efficacy vs. Tepezza at 24wk, and veligrotug's placebo-corrected rates of diplopia resolution and hearing... More